The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine

Revised Retinopathy Screening Guidelines State Risks Linked to Hydroxychloroquine, Chloroquine

November 16, 2016 • By Vanessa Caceres

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Monkey Business Images/shutterstock.com

Monkey Business Images/shutterstock.com

A large medical specialty society for ophthalmologists recently updated its recommendations for the screening of chloroquine (CQ) and hydroxychloroquine (HCQ) retinopathy.1

You Might Also Like
  • Hydroxychloroquine Retinopathy Still Alive and Well
  • Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine
  • Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus
Explore This Issue
November 2016
Also By This Author
  • ACR Convergence 2020: From Clinic to Capitol Hill Session Offers Insights into Advocacy, Regulatory Issues

The recommendations from the American Academy of Ophthalmology (AAO) affect patients who may use CQ or HCQ for rheumatoid arthritis or systemic lupus erythematosus (SLE), as well as some inflammatory and dermatologic conditions. The drugs are also used as anti-malarials. Retinopathy caused by these medications is not treatable, and toxicity can occur even after a patient has stopped using the agents.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The new guidelines were published in the June issue of the journal Ophthalmology.

The guidelines were last updated in 2011. The authors, led by Michael F. Marmor, MD, Department of Ophthalmology and Byers Eye Institute, Stanford University of Medicine, Palo Alto, Calif., decided to update the guidelines once again because of research published in 2014 that shed some new light on the topic.2 “The recent publication of a large demographic study has shown that toxicity is not rare among long-term uses of the drug, and the risk is highly dependent on the daily dose by weight,” the authors wrote.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the 2014 retrospective case-control study, the records of 2,361 patients who had used HCQ continuously for at least five years were reviewed. All patients had visual field testing or spectral-domain optical coherence tomography (SD OCT) performed. The overall prevalence of HCQ retinopathy was 7.5%; with a daily consumption of 4.0 to 5.0 mg/kg, retinal toxicity prevalence remained less than 2% in the first 10 years. However, that jumped to almost 20% after 20 years of use. The study also found other major risk factors for retinal toxicity, including kidney disease and concurrent tamoxifen therapy. The research suggested that HCQ retinopathy is more common than once thought, the authors concluded.2 They also said that daily consumption of 5.0 mg/kg based on real body weight or less is associated with a low risk for up to 10 years.

The New Guidelines

Under the revised guidelines, the AAO recommends the following to clinicians for the screening and monitoring of HCQ and CQ toxicity:

  • Keep the daily dosage of HCQ to 5.0 mg/kg or less of real body weight. Although there may be rare cases where higher doses are needed, clinicians should aim for a lower limit whenever possible.
  • All patients beginning long-term HCQ or CQ therapy should have a baseline eye exam in the first year of starting the drug. This helps document any complicating ocular conditions and establish a record of the fundus appearance and functional status, the authors wrote. “Most critical is fundus evaluation of the macula to rule out any underlying disease that might make use of these drugs unwise because of preexisting tissue damage or interference with the interpretation of screening tests.”
  • Baseline visual fields and SD OCT are not necessary unless abnormalities are present, such as a focal macular lesion or glaucoma.
  • If patients are taking the recommended dose, then annual screening is not necessary until there has been five years of exposure to HCQ or CQ. At that point, annual screenings can give ophthalmologists time to perform repeat tests or additional tests when results are suspicious.
  • More frequent screenings should be considered in patients with major risk factors, such as major weight loss, kidney disease and tamoxifen use. Clinicians should always check the dosage relative to weight.
  • Because there is a greater risk for toxicity beyond the macula in Asian patients, ophthalmologists should use wider test patterns (24–2 and 30–2) when performing visual fields in this patient group.
  • If definitive signs of retinopathy are found, the prescribing physician should work with the patient and their ophthalmologist regarding the need to halt the medication and to ensure that any potential disease flare-ups are managed.

The authors of the guidelines said their goal is not to discourage the use of HCQ and CQ. “Screening can be viewed as a means of helping patients to continue HCQ or CQ (by not stopping the drugs for certain findings) as much as a means of preventing serious retinal damage (by the early recognition of definitive findings),” they wrote.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Rheumatologists, Ophthalmologists Weigh In

The updated guidelines seem in step with today’s practice patterns but may require some adjustments, clinicians said.

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: American Academy of Ophthalmology, chloroquine, eye, guideline, HYDROXYCHLOROQUINE, ocular, patient care, recommendation, retinopathy, rheumatologist, risk, screening, usage, visionIssue: November 2016

You Might Also Like:
  • Hydroxychloroquine Retinopathy Still Alive and Well
  • Ocular Disease Monitoring Critical to Avoid Retinal Toxicity from Hydroxychloroquine
  • Rheumatologists Debate Hydroxychloroquine Dosing Guidelines for Lupus
  • Hydroxychloroquine Risk-Benefit Discussion, & a Handy Dosage App

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.